Hypercalcemia: Etiology, Classification, Diagnosis, and Management
Overview and Pathophysiology
Definition of Hypercalcemia:
- Defined as an abnormally elevated serum calcium concentration, specifically a total serum calcium concentration of or an ionized (free) calcium concentration of .
- Primary hyperparathyroidism and malignancy account for approximately of all documented cases.
True Hypercalcemia vs. Factitious Hypercalcemia:
- True Hypercalcemia:
- Characterized by elevated ionized calcium () or elevated corrected calcium (), irrespective of total serum calcium measurements.
- Clinically significant and may cause physiological dysfunction and symptomatology.
- Factitious Hypercalcemia (Pseudohypercalcemia):
- Characterized by an elevated total serum calcium concentration in the presence of a completely normal ionized calcium level (the non-protein bound, biologically and physiologically active fraction) or a normal albumin-corrected calcium level.
- Patients are clinically asymptomatic because physiologically active free ionized calcium is maintained within homeostatic limits.
- Pathogenesis involves elevations in circulating serum proteins that bind calcium, which artificially inflates total calcium levels:
- Hyperalbuminemia: Commonly observed in severe hemoconcentration or dehydration states.
- Paraproteinemia: Observed in plasma cell dyscrasias, most notably multiple myeloma, where circulating monoclonal immunoglobulins bind calcium ions.
- True Hypercalcemia:
Etiology and Classification
Etiological Classification Overview:
- Causes are systematically separated into PTH-mediated hypercalcemia (characterized by inappropriately normal or elevated parathyroid hormone levels) and non-PTH-mediated hypercalcemia (characterized by suppressed parathyroid hormone levels due to intact physiological negative feedback).
PTH-Mediated Hypercalcemia:
- Primary Hyperparathyroidism:
- Etiology: Solitary parathyroid adenoma ( of cases) or diffuse parathyroid hyperplasia (sporadic or associated with familial syndromes such as MEN1 or MEN2A).
- Pathophysiology: Autonomous oversecretion of parathyroid hormone () stimulates renal tubular calcium reabsorption, promotes skeletal calcium mobilization via osteoclastic resorption, and upregulates the renal expression of , leading to increased synthesis of () in the proximal tubules, which in turn enhances intestinal calcium and phosphate absorption.
- Clinical Course: Usually mild, insidious, and asymptomatic; detected incidentally on routine biochemical profiling.
- Tertiary Hyperparathyroidism:
- Etiology: Advanced chronic kidney disease (CKD) or end-stage renal disease (ESRD).
- Pathophysiology: Longstanding, untreated secondary hyperparathyroidism leads to chronic parathyroid gland hyperplasia and subsequent monoclonal transformation, resulting in autonomous, nonsuppressible parathyroid hormone secretion independent of serum calcium concentrations.
- Familial Hypocalciuric Hypercalcemia (FHH):
- Inactivating genetic defects in calcium sensing.
- Medication-Induced (Lithium):
- Reduces renal calcium excretion and shifts the set point of the calcium-sensing receptor () rightward in the parathyroid glands, requiring higher serum calcium levels to inhibit parathyroid hormone secretion.
- Primary Hyperparathyroidism:
Non-PTH-Mediated Hypercalcemia:
- Hypercalcemia of Malignancy:
- Typically manifests acutely with severe, symptomatic elevations in serum calcium.
- Paraneoplastic PTHrP Secretion: Most common cause ( of malignancy-associated cases). Malignant cells secrete parathyroid hormone-related protein (), which binds and activates the shared PTH/PTHrP receptor (PTH1R), mimicking parathyroid hormone action on bone and kidneys. Common etiologies include squamous cell carcinomas (lung, head and neck), renal cell carcinoma, bladder cancer, and ovarian cancer.
- Osteolytic Metastases: Direct osteolytic tumor invasion accompanied by local cytokine production (e.g., RANKL, TNF, IL-1) driving excessive osteoclastic bone resorption. Common etiologies include multiple myeloma, breast cancer, lymphoma, leukemia, and renal cell carcinoma.
- Paraneoplastic Production of Calcitriol: Extra-renal synthesis of active by tumor tissue. Common etiologies include Hodgkin and non-Hodgkin lymphomas, as well as ovarian dysgerminoma.
- Granulomatous Disorders:
- Etiologies include sarcoidosis, tuberculosis, berylliosis, and fungal granulomas.
- Pathophysiology: Unregulated expression of within activated mononuclear cells and macrophages inside granulomas catalyzes conversion of to independent of parathyroid hormone or negative feedback regulation.
- Medications and Intoxications:
- Thiazide Diuretics: Inhibit the cotransporter in the distal convoluted tubule, indirectly augmenting renal tubular calcium uptake and reducing renal calcium excretion.
- Exogenous Vitamin D Excess: Toxicity from high-dose ergocalciferol, cholecalciferol, or active metabolites leads to massive hyperabsorption of dietary calcium and phosphate in the small intestine.
- Exogenous Calcium and Antacids: Chronic excessive ingestion of calcium carbonate or calcium-containing antacids.
- Vitamin A Toxicity: Excess vitamin A and vitamin A derivatives (such as all-trans retinoic acid) directly stimulate osteoclast activity and induce excessive skeletal resorption.
- Thyrotoxicosis:
- Elevated thyroid hormones ( and ) directly stimulate osteoclasts, causing increased bone turnover, osteoclastic bone resorption, and skeletal demineralization.
- Long Periods of Immobilization:
- Lack of mechanical weight-bearing stress suppresses osteoblastic bone formation while shifting bone remodeling toward uncoupled osteoclastic resorption, leading to demineralization and hypercalcemia.
- Predominantly affects individuals with baseline high bone turnover states, such as growing adolescents, young adults, or patients with underlying Paget disease of bone.
- Milk-Alkali Syndrome:
- Historically or modernly caused by the consumption of large amounts of calcium supplements combined with absorbable alkali (such as calcium carbonate).
- Characterized clinically and biochemically by the classical triad of hypercalcemia, metabolic alkalosis, and renal insufficiency/acute kidney injury.
- Adrenal Insufficiency (Addison Disease):
- Proposed pathophysiological mechanisms:
- Hypovolemia and extracellular volume depletion lead to decreased glomerular filtration rate (), resulting in diminished filtered calcium load and a compensatory increase in proximal tubular calcium reabsorption.
- Increased activity leading to increased circulating calcitriol ().
- Decreased stanniocalcin levels (), removing an inhibitory regulator of calcium uptake.
- Proposed pathophysiological mechanisms:
- Hypercalcemia of Malignancy:
Etiology Mnemonic: "Thinking Chimpanzees!":
- Thinking: Thiazides, Thyroid (Thyrotoxicosis)
- C: Calcium supplementation
- H: Hyperparathyroidism (Primary or Tertiary)
- I: Immobilization, Inherited (Familial Hypocalciuric Hypercalcemia)
- M: Milk-alkali syndrome, Meds (Lithium, Thiazides)
- P: Paraneoplastic PTHrP
- A: Adrenal insufficiency
- N: Neoplasm (Multiple myeloma, breast, lung, leukemia, lymphoma)
- Z: Zollinger-Ellison syndrome (associated with MEN1 / primary hyperparathyroidism)
- E: Excessive vitamin D
- E: Excessive vitamin A
- S: Sarcoidosis & granulomatous diseases
Clinical Features and Severity Classification
Organ System Clinical Features:
- Renal and Urological Manifestations:
- Nephrolithiasis and nephrocalcinosis (calcium oxalate stones are more frequent than calcium phosphate stones).
- Polyuria and secondary polydipsia caused by calcium-induced nephrogenic diabetes insipidus (impaired aquaporin-2 expression and direct blunting of antidiuretic hormone / ADH sensitivity in the collecting ducts).
- Dehydration, prerenal azotemia, oliguria, or anuria in advanced crisis.
- Musculoskeletal Manifestations:
- Diffuse bone pain, arthralgias, and myalgias.
- Pathological fractures and osteopenia/osteoporosis due to enhanced osteoclastic demineralization.
- Gastrointestinal Manifestations:
- Constipation (due to decreased gastrointestinal smooth muscle contractility).
- Abdominal pain, nausea, vomiting, and anorexia.
- Peptic ulcer disease (calcium directly stimulates gastrin release from G cells, promoting gastric acid secretion).
- Acute pancreatitis (calcium deposition in pancreatic ducts and premature intrapancreatic trypsinogen activation).
- Neuropsychiatric Manifestations:
- Early features: Anxiety, depression, fatigue, psychomotor slowing, and cognitive impairment.
- Severe progression: Lethargy, somnolence, delirium, psychosis, obtundation, and coma (pathognomonic of hypercalcemic crisis).
- Neuromuscular and Cardiovascular Manifestations:
- Diminished neuromuscular and smooth muscle excitability leading to skeletal muscle weakness, hyporeflexia, and paresis.
- Shortened QT interval on electrocardiography.
- Arrhythmias and severe bradycardia.
- Appearance of Osborn waves () in severe hypercalcemic states.
- Renal and Urological Manifestations:
Severity Stratification and Clinical Pearls:
- Mild Hypercalcemia:
- Total serum calcium: .
- Ionized calcium: .
- Clinical presentation: Typically asymptomatic; may exhibit subtle constitutional symptoms.
- Moderate Hypercalcemia:
- Total serum calcium: .
- Ionized calcium: .
- Clinical presentation: May be well-toler
- Mild Hypercalcemia: